BiotechTube

Adalimumab + Risankizumab

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Juvenile Psoriatic Arthritis

Conditions

Juvenile Psoriatic Arthritis

Trial Timeline

Jul 8, 2024 → Oct 1, 2028

NCT ID
NCT06100744

About Adalimumab + Risankizumab

Adalimumab + Risankizumab is a phase 3 stage product being developed by AbbVie for Juvenile Psoriatic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06100744. Target conditions include Juvenile Psoriatic Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06100744Phase 3Recruiting

Competing Products

20 competing products in Juvenile Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
69
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
AdalimumabEisaiPhase 3
77
AbataceptOno PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
BaricitinibEli LillyPhase 3
77
Baricitinib + TocilizumabEli LillyPhase 3
77
adalimumab + MethotrexateAbbViePre-clinical
23
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
77
AdalimumabAbbViePhase 3
77
naproxen + esomeprazoleAstraZenecaPhase 1
33
Alendronate (Fosamax)MerckPre-clinical
23
canakinumabNovartisPhase 3
77
SecukinumabNovartisPhase 1
33
ACZ885 150 mg (Canakinumab)NovartisPhase 3
77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85